A new kind of genetic analysis has identified a gene that likely contributes to risk for amyotrophic lateral sclerosis. As reported in the October 22 Neuron, geneticists scanning the exomes of ALS cases and controls found that people with the disease were far more likely to contain variants in the tubulin, alpha 4A gene (TUBA4A). Experts who spoke with Alzforum said that although the evidence is strong, an independent study pointing to TUBA4A would be needed to confirm the association. Senior author John Landers of the University of Massachusetts (UMass) Medical School in Worcester also urged caution, calling TUBA4A a risk factor but not necessarily a causative gene. TUBA4A joins several other cytoskeleton-related genes that have been implicated in neurodegeneration, bolstering the theory that cellular struts and beams keep neurons healthy.
Altered Interface: Alpha-tubulin (light blue) interacts with the β isoform (green) and also kinesin (orange). The red residues indicate those affected by human mutations or truncations found in ALS cases. [Image courtesy of Neuron, Smith et al.]
Traditionally, one way geneticists found new disease genes was by analyzing large kindreds that had been affected. As recently as March of this year, researchers in Italy and the United States used this approach to find mutations in Matrin 3, a DNA- and RNA-binding protein, which associate with ALS (Johnson et al., 2014). However, geneticists have already studied most of the large U.S. and European families with ALS. “We had to come up with an alternative strategy,” said Landers.
Landers began an international collaboration with co-senior authors Vincenzo Silani of the University of Milan Medical School and Christopher Shaw of King’s College London. Their study is one of the first to use a method called exome-wide rare variant analysis (Panoutsopoulou et al., 2013; Stitziel et al., 2011). In this technique, researchers compare the exomes of people with the disease with those from healthy controls. Genes more frequently altered in people with ALS are deemed likely to influence disease risk. “This does not say that any one of those variants, in particular, is causative,” cautioned Landers. He said some variants may turn out to be harmless. The researchers and Neuron have produced a video abstract that explains the strategy.
The first step for joint first authors Bradley Smith, Athina Gkazi, and Simon Topp of King’s College, Nicola Ticozzi of the University of Milan Medical School, and Claudia Fallini of UMass Medical School was to read the exomes of 363 people who had inherited ALS but had no mutations in any of the known ALS genes. To find genes that varied more in ALS, they compared those sequences to 4,300 control exomes from a National Institutes of Health database. To avoid benign changes in the genetic code, the authors limited their analysis to variants predicted to alter protein structure or function by the bioinformatics tool PolyPhen-2.
The researchers built in a positive control by including exome data from people with mutations in known ALS genes—six people who have familial ALS caused by mutations in superoxide dismutase 1, and three people with mutations in valosin-containing protein. Sure enough, the exome-wide analysis found more variation in these two genes in ALS cases than controls. It also identified matrin 3 as an ALS gene, further validating the technique.
The analysis also identified a new ALS gene candidate in TUBA4A. No controls carried the TUBA4A variants that are predicted to disrupt the protein, but four cases did. To check their results, the authors repeated the analysis in a new dataset with 272 familial ALS cases and 5,510 controls. Again, TUBA4A stood out. They found two variants in people with ALS, and two in the much larger control group, indicating a far higher frequency of variation in people with the disease.
“This manuscript provides a novel approach to identifying ALS-linked genes,” Aaron Gitler of Stanford University in Palo Alto, California, wrote in an email to Alzforum. “The race is now on to figure out how tubulin fits into ALS pathogenesis, and the field must now assess the TUBA4A gene in additional ALS patient cohorts.” (See full comment below.)
Landers and colleagues also identified a handful of genes that were enriched in ALS cases, but did not pass statistical tests for significance. These include genes for serine/threonine kinase 24 (STK24), which participates in apoptosis, and a protein that goes by the mouthful leucine rich repeat (in flightless I homolog ) interacting protein 1 (LRRFIP1), a DNA- and RNA-binding protein. With analysis of more cases, those genes might prove significant, Landers suggested. In fact, neither VCP nor matrin 3 was statistically significant in this cohort.
Overall, the authors found seven different TUBA4A variants in people with familial ALS. Six of these were predicted to damage the protein. In one person with sporadic ALS they also discovered an eighth variant, a valine rather than a glycine at position 43. PolyPhen-2 predicted this substitution was unlikely to alter protein function. One of the six proposed dysfunctional variants also occurred in control exomes, while another showed up in one person with familial ALS but not in that person’s cousin, who also had the disease. These two might also be neutral variants, the authors suggested. Most of the variants occurred in the carboxyl end of the protein, which makes contact with other tubulin subunits and associated proteins, such as kinesins (see image above).
“If the results are independently replicated, then it would be clear that the TUBA4A gene is involved in ALS,” commented Rita Guerreiro of University College London, who was not involved in the study. “However, it is unclear what role each of the variants identified has in disease.”
TUBA4A encodes one of eight human α-tubulins, which polymerize with β-tubulins to make the microtubule cytoskeleton. TUBA4A is highly expressed in brain. Landers said the researchers immediately surmised that mutations might have a dominant-negative effect, by interfering with assembly or stability of the microtubule network. Fallini and colleagues studied microtubule dynamics of several of the variants. In mouse primary motor neurons, the wild-type and G43V TUBA4A assembled into microtubules normally. The other variants did not integrate into microtubules as efficiently, and unlike normal tubulin, they also appeared diffusely throughout the cytosol. A premature stop codon mutant, tryptophan-407-X, did not form part of microtubules, and instead made ubiquitinated cytoplasmic inclusions in many cells.
Fallini observed that some of the mutants also destabilized the microtubule cytoskeleton, and interfered with the assembly of the centrosome, the cell’s microtubule organizing center. The authors conclude that the variants of TUBA4A associated with ALS weaken the microtubule network. Landers speculated that the mutants might hamper the incorporation of normal tubulin or slow microtubule extension.
There is precedent for cytoskeletal genes being involved in neurodegeneration. At least seven other tubulins have been linked to neurological “tubulinopathies” (reviewed in Breuss and Keays, 2014). Microtubule-associated proteins also have been implicated in neurological disease. Mutations in spastin cause hereditary spastic paraplegia (Wharton et al., 2003) and tau mutations cause some cases of frontotemporal dementia. FTD and ALS share disease genes, and people with one condition often exhibit symptoms of the other malady. Notably, two of the ALS cases in the study also exhibited dementia. Guerreiro suggested it might be worth screening for TUBA4A mutations in people with FTD.
Landers and colleagues are not the only ones finding novel ways to identify ALS genes. Gitler has hunted for ALS-linked mutations without relying on large kindreds by focusing on “trios,” people with sporadic ALS and their parents (see May 2013 news story). Writing in the October 2014 PLoS Genetics, Gitler, first author Julien Couthouis, and colleagues from Stanford describe their latest strategy. Rather than looking at the whole exome, they took a candidate approach, sequencing the exons of 169 genes known or suspected to contribute to ALS. Like the authors of the Neuron study, they looked for genes that displayed more variation in 242 cases than in 129 controls. “The method is not very good for gene discovery, but for candidate screening it is perfect,” said Couthouis. “You just have to sequence what you need.”
The researchers found several novel variants. For example, they observed that several point mutations in the ataxin-2 gene occur more frequently in ALS. This supports prior analyses that have linked repeat expansions in ataxin-2 enhance to ALS risk (see Aug 2010 news story; Neuenschwander et al., 2014). They also found variants of a gene called ALS2, which has been associated with juvenile disease, in their cases. That suggests the gene could contribute to adult ALS risk, as well. The authors also identified more variants of genes they picked out in the trio study. These and other novel variants are likely, but not proven, to be ALS-associated genes, said Couthouis.—Amber Dance
To view commentaries, primary articles and linked stories, go to the original posting on Alzforum.org here.
Copyright © 1996–2018 Biomedical Research Forum, LLC. All Rights Reserved.